In a global clinical trial, GBM AGILE (Glioblastoma Adaptive Global Innovative Learning Environment), Henry Ford Cancer Institute is the first to activate two new treatments for glioblastoma. The GBM AGILE trial allows for global collaboration and has the potential to increase breakthroughs in the research and treatment for glioblastoma. This trial will eventually enroll patients at 35 sites in the United States, Canada, Europe, and China.
The two treatments tested in this trial are VAL-083 from Kintara Therapeutics, Inc. and paxalisib from Kazia Therapeutics Limited. Both interventions are being tested in newly-diagnosed and recurrent glioblastoma.
Learn more about this innovative trial here.